Acalabrutinib in patients with mantle cell lymphoma subjected to allogeneic hematopoietic cell transplantation. a phase 2 study by the Polish Lymphoma Research Group (PLRG12 trial)
Annals of Hematology · 17.07.2026 · 105 (11)
DOI: 10.1007/s00277-026-07178-8 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Annals of Hematology, online erschienen am 17.07.2026. Verfasst von Sebastian Giebel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Gliwice Branch, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland. sgiebel@io.gliwice.pl. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Hematopoietic Stem Cell Transplantation, Benzamides, Pyrazines. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca Pharma Poland.
Abstract (Originalsprache)
This phase 2 trial evaluated the safety and efficacy of acalabrutinib used to reduce tumor burden before allogeneic hematopoietic cell transplantation (allo-HCT) and as a maintenance therapy after transplantation in patients with relapsed/refractory mantle cell lymphoma (R/R MCL). Patients were treated with acalabrutinib 100 mg BID for 3-6 months. Those achieving complete or partial response (CR, PR) were referred for allo-HCT. Acalabrutinib was restarted 30-90 days after allo-HCT and administered for the subsequent 9 months. The remaining patients continued acalabrutinib until progression or unacceptable toxicity. Out of the 28 included patients, 16 subjects (57%) responded, with CR in 14 cases (50%) and PR in 2 cases (7%). Fifteen patients (54%) underwent allo-HCT. Twenty-three patients (79%) had grade 3-4 adverse events, most commonly neutropenia (34%) and infections (21%). Five patients died of treatment-related toxicity, including infections in 4 cases. he probabilities of overall and progression-free survival (PFS) at 2 years were 60% (95%CI, 40-79) and 41.5% (23-60), respectively. PFS rate for patients treated with allo-HCT was 67% (44-92) at 18 months. Acalabrutinib generates high response rates in patients with R/R MCL and may serve as a "bridge" to allo-HCT and maintenance after transplantation. Infections are most frequent life-threatening complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gliwice Branch, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland. sgiebel@io.gliwice.pl.
- Department of Bone Marrow Transplantation and Onco-Hematology, Gliwice Branch, Maria Sklodowska-Curie National Research Institute of Oncology, Str. Wybrzeze Armii Krajowej, Gliwice, 44-102, Poland. sgiebel@io.gliwice.pl.
- Wroclaw Medical University, Wroclaw, Poland.
- National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland.
- University Clinical Hospital, Poznań, Poland.
- Medical University of Lublin, Lublin, Poland.
Förderung
- AstraZeneca Pharma Poland
Zitieren
APA
Giebel, S., Czyż, A., Hus, I., Gil, L., Giannopoulos, K., Romejko-Jarosińska, J., Majcherek, M., Szeremet, A., Wache, A., Kwaśnik, P., Swoboda, R., & Jurczak, W. (2026). Acalabrutinib in patients with mantle cell lymphoma subjected to allogeneic hematopoietic cell transplantation. a phase 2 study by the Polish Lymphoma Research Group (PLRG12 trial). Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07178-8
Vancouver
Giebel S, Czyż A, Hus I, Gil L, Giannopoulos K, Romejko-Jarosińska J, et al. Acalabrutinib in patients with mantle cell lymphoma subjected to allogeneic hematopoietic cell transplantation. a phase 2 study by the Polish Lymphoma Research Group (PLRG12 trial). Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07178-8
BibTeX
@article{Giebel2026,
author = {Giebel, Sebastian and Czyż, Anna and Hus, Iwona and Gil, Lidia and Giannopoulos, Krzysztof and Romejko-Jarosińska, Joanna and Majcherek, Maciej and Szeremet, Agnieszka and Wache, Anna and Kwaśnik, Paulina and Swoboda, Ryszard and Jurczak, Wojciech},
title = {Acalabrutinib in patients with mantle cell lymphoma subjected to allogeneic hematopoietic cell transplantation. a phase 2 study by the Polish Lymphoma Research Group (PLRG12 trial)},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {11},
doi = {10.1007/s00277-026-07178-8}
}
EUVIMED